Bioventus (NASDAQ:BVS) vs. RenovoRx (NASDAQ:RNXT) Head-To-Head Review

RenovoRx (NASDAQ:RNXT) and Bioventus (NASDAQ:BVS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Earnings and Valuation

This table compares RenovoRx and Bioventus”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12 million	66.89	-$11.17 million	($0.31)	-5.35
Bioventus	$581.85 million	2.00	$22.73 million	$0.77	17.94

Bioventus has higher revenue and earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for RenovoRx and Bioventus, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1	0	2	1	2.75
Bioventus	0	1	5	0	2.83

RenovoRx presently has a consensus target price of $8.50, suggesting a potential upside of 412.05%. Bioventus has a consensus target price of $16.80, suggesting a potential upside of 21.65%. Given RenovoRx’s higher possible upside, equities analysts clearly believe RenovoRx is more favorable than Bioventus.

Volatility and Risk

RenovoRx has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500.

Insider & Institutional Ownership

3.1% of RenovoRx shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 9.4% of RenovoRx shares are held by insiders. Comparatively, 33.5% of Bioventus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares RenovoRx and Bioventus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RenovoRx	-621.71%	-135.11%	-101.91%
Bioventus	9.36%	28.08%	9.82%

Summary

Bioventus beats RenovoRx on 11 of the 15 factors compared between the two stocks.

About RenovoRx

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

About Bioventus

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company’s restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician’s office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.